Exagen Inc

Exagen Inc

XGN - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$99.8M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Exagen IncExagen Inc-7.1--132%2.12.2
$11.00

Target Price by Analysts

166.3% upsideExagen Target Price DetailsTarget Price
$9.37

Current Fair Value

126.9% upside

Undervalued by 126.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$99.80 Million
Enterprise Value$101.87 Million
Earnings per Share$-0.93
Beta2.24
Outstanding Shares24,164,569

Return

Return on Equity-131.92%ROE
Return on Assets-32.83%
Return on Invested Capital-29.25%

Valuation & Multiples

P/E Ratio-7.09P/E Ratio
PEG66.86PEG
Price to Sales2.07Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1.41
Enterprise Value to EBIT-8.24
Enterprise Value to Net Income-6
Total Debt to Enterprise0.3
Debt to Equity2.19Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 10, 2026
EPS
-$0.25
Est. -$0.18
Revenue
$18.42 M
Est. $18.34 M

Next Earnings Call

Expected Date
March 9, 2027
EPS Estimate
-$0.19
Consensus analyst estimate
Revenue Estimate
$18.11 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1.50%▼ 31.39%
Total Invested$2.95M▼ 92.02%
Investors Holding10▼ 47.00%

About Exagen Inc

182 employees
CEO: Fortunato Rocca

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and i...

Exagen Insider Information FAQ

Stockcircle tracks 4 top investors with a current 13F position in Exagen. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 3 open-market insider purchases and 3 open-market insider sales for Exagen in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.